SCHEMBL1502818

SCHEMBL1502818

CCCCCCCC/C=C(/CCCCCCCC)O/C(=C\CCCCCCCC)CCCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.45
TERT O14746 3/20 0.44
PTPN1 P18031 3/20 0.44
PPARG P37231 3/20 0.44
PPARD Q03181 3/20 0.44
PPARA Q07869 3/20 0.44
CYP1A2 P05177 2/20 0.44
MAPT P10636 2/20 0.44
CYP2C19 P33261 2/20 0.44
BLM P54132 2/20 0.44
HSD17B10 Q99714 2/20 0.44
FABP4 P15090 2/20 0.44
FAAH O00519 2/20 0.44
KMT2A Q03164 2/20 0.44
GMNN O75496 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11130007 1.00 EP300 (0.45) EP300TERTPTPN1PPARGPPARD
SCHEMBL11005625 1.00 EP300 (0.45) EP300TERTPTPN1PPARGPPARD
SCHEMBL11130016 1.00 EP300 (0.45) EP300TERTPTPN1PPARGPPARD
SCHEMBL11005612 1.00 EP300 (0.45) EP300TERTPTPN1PPARGPPARD
SCHEMBL11805820 1.00 EP300 (0.45) EP300TERTPTPN1PPARGPPARD
SCHEMBL4864006 0.92 LMNA (0.48) EP300PPARGPPARACYP1A2MAPT
Ether SCHEMBL11035818 0.92 FAAH (0.40) EP300TERTPTPN1PPARGPPARD
SCHEMBL20476197 0.92 LMNA (0.48) EP300PPARGPPARACYP1A2MAPT
SCHEMBL5977367 0.91 TSHR (0.57) EP300TERTPTPN1PPARGPPARD
SCHEMBL27854614 0.91 TSHR (0.57) EP300TERTPTPN1PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0233629-B1 COMPOSITIONS FOR TREATEMENT OF VIRAL AND CANCEROUS SKIN LESIONS AND THE LIKE EXOVIR, INC. (US) 1991-10-23 EP claimed
US-20230372348-A1 LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS GABATHER AB (SE) 2023-11-23 US disclosed
EP-4225275-A1 LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS Gabather AB (SE) 2023-08-16 EP disclosed
WO-2022074457-A1 LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS GABATHER AB (SE) 2022-04-14 WO disclosed
CN-109876149-A A kind of pharmaceutical carrier and preparation method of apiolin 山东师范大学 2019-06-14 CN disclosed
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2019-04-18 US disclosed
US-10259856-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2019-04-16 US disclosed
US-9688737-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2017-06-27 US disclosed
EP-2910570-B1 Protease stabilized, acylated insulin analogues NOVO NORDISK AS (DK) 2016-10-12 EP disclosed
EP-2910571-B1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2016-10-05 EP disclosed
US-20080064760-A1 Spontaneously Dispersible Pharmaceutical Composition LI PING 2008-03-13 US disclosed
EP-1807049-A1 SPONTANEOUSLY DISPERSIBLE PHARMACEUTICAL COMPOSITIONS Novartis AG (CH) 2007-07-18 EP disclosed
EP-1202719-B1 ANESTHETIC COMPOSITION FOR INTRAVENOUS INJECTION COMPRISING PROPOFOL KUHNIL PHARMACEUTICAL CO LTD (KR) 2006-05-31 EP disclosed
WO-2006050123-A1 SPONTANEOUSLY DISPERSIBLE PHARMACEUTICAL COMPOSITIONS NOVARTIS AG (CH) 2006-05-11 WO disclosed
US-6743436-B1 Anesthetic composition for intravenous injection comprising propofol KUHNIL PHARM. CO., LTD. (KR) 2004-06-01 US disclosed
CN-1149984-C Anesthetic compositions for intravenous injection containing propofol ��һ��������ҩ��ʽ���� 2004-05-19 CN disclosed
EP-1202719-A4 ANESTHETIC COMPOSITION FOR INTRAVENOUS INJECTION COMPRISING PROPOFOL KUHNIL PHARMACEUTICAL CO LTD (KR) 2004-03-17 EP disclosed
CN-1356896-A Anesthetic compsn. for intravenous injection comprising propofol KUHNIL PHARM CO LTD (KR) 2002-07-03 CN disclosed
EP-1202719-A1 ANESTHETIC COMPOSITION FOR INTRAVENOUS INJECTION COMPRISING PROPOFOL KUHNIL PHARMACEUTICAL CO., LTD. (KR) 2002-05-08 EP disclosed
WO-2000078301-A1 ANESTHETIC COMPOSITION FOR INTRAVENOUS INJECTION COMPRISING PROPOFOL KUHNIL PHARM. CO., LTD. (KR) 2000-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064760-A1 Spontaneously Dispersible Pharmaceutical Composition ABCB11, ABCG2, LIPA EP300 1478/4885TERT 4136/4885PTPN1 3160/4885
US-20230372348-A1 LIPID FORMULATIONS OF TRIAZOLOQUINAZOLINONE COMPOUNDS SOAT1, DGAT1, CPT1A EP300 1271/4885TERT 3463/4885PTPN1 1262/4885
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE EP300 2091/4885TERT 3566/4885PTPN1 4022/4885
US-10259856-B2 Protease stabilized acylated insulin analogues IAPP, IDE, LIPE EP300 1705/4885TERT 3341/4885PTPN1 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.